Trial intelligence / Profile preview

One-year randomized comparison of insulin detemir vs insulin glargine in basal-bolus therapy for type 1 diabetes

2004-000086-35Phase 3Completed

Sponsor
Novo Nordisk
Start
Jun 2004
Modality
Recombinant Proteins and Enzymes
Countries
1
01

Overview

Phase 3, randomised, open-label trial of insulin detemir in diabetes mellitus type 1 (T1D) (2 arms), sponsored by Novo Nordisk. Primary endpoint: HbA1c after 52 weeks of treatment. Started Jun 2004; status: completed.

02

Drugs

insulin detemir
03

Conditions

diabetes mellitus type 1 (T1D)

Beyond the preview

Go deeper on 2004-000086-35.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2004-000086-35.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call